MIUC: Risk of Recurrence After Radical Cystectomy
An expert discusses how patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical cystectomy face a significant recurrence risk. High-risk factors include advanced stage, lymph node involvement, and positive surgical margins. Neoadjuvant cisplatin-based chemotherapy can improve survival but does not eliminate recurrence risk. Other predictors include lymphovascular invasion, variant histology, and systemic inflammation markers.
Video Player is loading.
Video content above is prompted by the following:
- What is the risk of recurrence for patients with muscle-invasive urothelial carcinoma who undergo radical cystectomy with or without neoadjuvant cisplatin-based chemotherapy? (Renner 2021; Kim 2015; Bellmunt 2022)
- What factors put patients at higher risk for recurrence?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: Patient Counseling
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
Related Content
